Podcasts about ucsf

  • 1,659PODCASTS
  • 5,009EPISODES
  • 39mAVG DURATION
  • 1DAILY NEW EPISODE
  • Jul 22, 2025LATEST

POPULARITY

20172018201920202021202220232024

Categories



Best podcasts about ucsf

Show all podcasts related to ucsf

Latest podcast episodes about ucsf

The ABMP Podcast | Speaking With the Massage & Bodywork Profession
Ep 516 – What Inspires You to Help Others with Kristin Coverly

The ABMP Podcast | Speaking With the Massage & Bodywork Profession

Play Episode Listen Later Jul 22, 2025 29:55


Join Kristin Coverly as she speaks with the 2024 Massage is for EveryBody award winners about what inspires them to give back to their communities, as well as their advice for how you can get started, too! Resources: ABMP Education Center: https://www.abmp.com/learn/ ABMP Massage is for EveryBody Week: https://www.abmp.com/massage-week-intro 2024 Massage is for EveryBody Winners:  https://www.abmp.com/massage-week-awards-2024 Healwell's Massage Palliative Advanced Training for Healthcare (MPATH): https://mpath.healwell.org/  Host: Kristin Coverly, LMT is a massage therapist, educator, and the director of professional education at ABMP. She loves creating continuing education courses, events, and resources to support massage therapists and bodyworkers as they enhance their lives and practices. Contact her at ce@abmp.com. Guests: Nicole Kurth Nicole Kurth is a massage therapist who works with pediatric hospice and palliative care patients on the Pediatric Hospice Palliative Care team at By the Bay Health, a UCSF-affiliated nonprofit home health organization. By the Bay Health: https://bythebayhealth.org/pediatrics-care-health-professionals/  Singeli Zaparaniuk Singeli Zaparaniuk is a massage therapist who works with suicide loss survivors. Elevate Healing Arts: https://www.elehealing.com/ Dannie Horton Dannie Horton is the co-founder of the Cleveland Embodiment Collective, a worker-owned collective of massage therapists that offers cost-free and sliding-scale sessions. Cleveland Embodiment Collective: https://www.clevelandembodiment.org/   Julia Semple Julia Semple is a practitioner who, for the 2024 Massage is for EveryBody Week event, held a contest to introduce massage to community members with limited access. Therapeutic Massage of Northern Colorado:  https://www.therapeuticmassageofnoco.com/   Sponsors:   Anatomy Trains: www.anatomytrains.com    PMNT: www.pmnt.org   MassageBook: www.massagebook.com  

Knowledge on the Go
AI in healthcare

Knowledge on the Go

Play Episode Listen Later Jul 21, 2025 18:11


AI is advancing rapidly in the healthcare space, raising important questions about how it will be used responsibly and effectively. Host Courtney Furrow White is joined by Sarah Pollet and Julia Bongiorno from UCSF to explore the evolving role of AI in clinical environments. Together, they break down the development of UCSF's IMPACC framework, a platform designed to evaluate and guide enterprise AI implementation. The conversation dives into what it takes to make AI safe, reliable, and trustworthy, not only for patients, but for the frontline staff who rely on these tools.   Guest speakers: Julia Bongiorno, PMP, MSHC Health AI Program Supervisor (Interim) UCSF Health   Sarah Pollet, MPH Program Director UCSF AI Impact & Monitoring (IMPACC)   Host: Courtney Furrow White MPM, RN Senior Director, Performance Improvement Programs Vizient   Show notes:  [1:47] Overview of UCSF's AI I-M-P-A-C-C framework and how it informs future deployments. [3:02] UCSF's approach to AI governance emphasizes safety, ethics and active research. [4:03] What it takes to ensure AI tools are reliable and clinically trusted. [6:41] Providers seek AI tools that reduce cognitive burden and improve workflows. [10:43] Educating patients on AI while reflecting on tools that failed to deliver. [13:01] How AI is shaping the nurse experience through practical tool integration. [15:44] Advice for other organizations on implementing AI responsibly and effectively.   Links | Resources: Contacting Knowledge on the Go: picollaboratives@vizientinc.com   Subscribe Today! Apple Podcasts Spotify Android RSS Feed

Network Capital
How to Raise Happy and Successful Children: Esther Wojcicki on Parenting, Grief, and Growth

Network Capital

Play Episode Listen Later Jul 19, 2025 61:19


Esther Wojcicki is a renowned educator and journalist, best known for her transformative parenting philosophy outlined in her books In this episode, she shares the principles that guided her as a mother to Susan Wojcicki, former CEO of YouTube, Anne Wojcicki, founder of 23andMe, and Dr Janet Wojcicki, a professor of paediatrics at UCSF.She reflects on how childhood trauma, loss and adversity can be met with trust, respect, independence, collaboration and kindness—the values at the heart of her TRICK framework. We also explore how her philosophy contrasts with more authoritarian approaches to parenting, such as those advanced by Amy Chua in Battle Hymn of the Tiger Mother. Esther argues that success does not require pressure or fear, but rather autonomy, connection, and trust.Esther also discusses grief - a constant in most of our lives. This conversation goes well beyond parenting. It is about finding strength through meaning, creating space for healing, and choosing stories that uplift rather than confine. Esther's insights offer a profound reminder that while loss is part of life, it does not have to define it.

The Third Wave
Robin Carhart-Harris, Ph.D. - SSRIs vs. Psychedelics: From Blunting to Rebooting

The Third Wave

Play Episode Listen Later Jul 18, 2025 58:43


In this episode of The Psychedelic Podcast, Paul F. Austin is joined by renowned neuroscientist Dr. Robin Carhart-Harris and microdosing policy advocate John Downs for a replay of a live event originally held on June 10th, Microdosing vs. SSRIs: What's Happening in the Brain and Why It Matters. Find full show notes and links here: https://thethirdwave.co/podcast/episode-312b/?ref=278 Together, they explore the scientific distinctions between SSRIs and psychedelics, focusing on neuroimaging, brain entropy, emotional processing, and the REBUS model. Dr. Carhart-Harris shares key insights from landmark studies on psilocybin therapy and discusses the evidence (and limitations) around microdosing. John Downs closes the conversation with an update on the Microdosing Collective's efforts to shift policy and expand access. Robin Carhart-Harris, PhD is a neuropharmacologist, psychologist, and Ralph Metzner Distinguished Professor in Neurology and Psychiatry at the University of California, San Francisco. He leads the Psychedelics Division at UCSF's Neuroscape and formerly founded and led the Centre for Psychedelic Research at Imperial College London. John Downs is Executive Director of the Microdosing Collective, advocating for responsible policy reform and legal access to microdosing. With 25 years' experience in sales, business development, and emerging markets, John helps individuals optimize mindset, performance, and purpose. Episode Highlights: Why SSRIs blunt, while psychedelics reset emotional processing How psilocybin compares to antidepressants in clinical trials Brain entropy, plasticity, and the REBUS model explained The role of the default mode network in mental health Why microdosing research is still so limited Ketamine vs. psilocybin: differences in brain mechanisms Is serotonin syndrome a real microdosing risk? Can psychedelics reverse long-term SSRI effects? The Microdosing Collective's mission for policy reform What Robin Carhart-Harris' upcoming book will explore Episode Links: Robin's lab & upcoming book Microdosing Collective Join Dr. Robin Carhart-Harris at our Practitioner Intensive (November 5–10, Costa Rica) Episode Sponsors: Golden Rule Mushrooms - Get a lifetime discount of 10% with code THIRDWAVE at checkout Psychedelic Coacing Isntitute's  Intensive for Psychedelic Professionals in Costa Rica - a transformative retreat for personal and professional growth.

Commonwealth Club of California Podcast
Dr. Monica Gandhi: The Impact on American Science and Medicine of the Current Administration

Commonwealth Club of California Podcast

Play Episode Listen Later Jul 17, 2025 53:38


Research funded by the federal government has been crucial in many of the defining technologies of our time: the internet, A.I., crispr, Ozempic, and the mRNA vaccines first used widely in the COVID pandemic. Between 2010 and 2019, more than 350 drugs were approved in the United States, and virtually all of them could trace their roots to the National Institutes of Health (NIH). Now this administration is endangering our health by cutting funds to academic medical centers. Moreover, there are threats to Medicaid, as well as ongoing cuts to the Centers for Disease Control (CDC). Many universities have paused hiring due to the uncertainty at the NIH and are curtailing graduate programs. Biotech investors are warning of a contraction in medical innovation. NIH grants have been terminated on ideological grounds, which have resulted in clinical trials shutting down. Global health programs worldwide have been cut. A discussion on these destructive policies on medicine in our country is needed. About the Speaker Monica Gandhi M.D., M.P.H., is a professor of medicine and associate chief in the Division of HIV, Infectious Diseases, and Global Medicine at the University of California, San Francisco (UCSF). She is also the director of the UCSF Center for AIDS Research (CFAR) and the medical director of the HIV Clinic ("Ward 86") at San Francisco General Hospital. She serves as the associate program director of the ID fellowship at UCSF. Her research focuses on HIV treatment and prevention optimization, HIV and women, adherence measurement in HIV and TB, adherence interventions, and on optimizing the use of long-acting antiretroviral therapy (ART). She is a long-standing NIH-funded researcher. Commonwealth Club World Affairs of California is a nonprofit public forum; we welcome donations made during registration to support the production of our programming. A Health & Medicine Member-led Forum program. Forums and Chapters at the Club are organized and run by volunteer programmers who are members of The Commonwealth Club, and they cover a diverse range of topics. Learn more about our Forums. Commonwealth Club World Affairs is a public forum. Any views expressed in our programs are those of the speakers and not of Commonwealth Club World Affairs. OrganizerMichael Baker  Learn more about your ad choices. Visit megaphone.fm/adchoices

6-8 Weeks: Perspectives on Sports Medicine
When Do You Fix An AC Joint Injury?

6-8 Weeks: Perspectives on Sports Medicine

Play Episode Listen Later Jul 17, 2025 18:12


What is an AC joint injury? Do you ever need to fix it? Listen to our latest podcast as Dr Brian Feeley and Dr Drew Lansdown break down treatment of this injury.

The OJSM Hot Corner
“The Formal EU-US Meniscus Rehabilitation 2024 Consensus: An ESSKA-AOSSM-AASPT Initiative Part II – Preventative, Nonoperative Treatment and Return to Sport” with Author, Dr. Benjamin Ma, MD , PhD

The OJSM Hot Corner

Play Episode Listen Later Jul 17, 2025 24:19


Meniscus tears can be confusing. They can occur with trauma or not, they come in a variety of shapes and locations which can influence treatment options and outcomes profoundly, and the right treatment remains a matter of great debate. The literature is likewise confusing, and historically has been heterogeneous. Dr. Benjamin MA, MD, PhD from the famed UCSF joins us to discuss an international multi-society expert panel he took part in to generate consensus statements regarding meniscus tear treatment. The consensus statements give all of us in the Sports Medicine world some guidance and reassurance for our approach to this seemingly simple structure, the meniscus, that, when torn, is full of complexities. 

How Women Inspire: Invest, Lead, Give
Transitioning from Academia to Startups with Grace Wei

How Women Inspire: Invest, Lead, Give

Play Episode Listen Later Jul 16, 2025 22:06


Are you a woman leader or entrepreneur considering a career pivot, especially from academia to the dynamic startup world? Do you wonder how to navigate this transition, build crucial relationships, and drive innovation in a new industry? This episode of How Women Inspire addresses these very challenges, offering invaluable insights into making a successful leap and fostering meaningful connections.This week's episode 177 of How Women Inspire Podcast is about transitioning from academia to startups! In this episode of How Women Inspire Podcast, Grace Wei is sharing the importance of building relationships and maintaining connections with experts and mentors. and actionable steps you can take right now to build a team culture at your startup. Grace Wei has held the position of COO at Encellin since 2016. Prior to that, Grace worked as a biologist at UCSF from 2005 to 2015. Grace Wei has a Bachelor's Degree in Human Genetics from McGill University and a Ph.D. in Molecular and Cellular Biology from the University of Chicago. Grace also completed programs at Stanford University Graduate School of Business and Y Combinator.Some of the talking points Julie and Grace go over in this episode include:Why building and maintaining strong relationships is paramount for founders and leadersThe unique benefits of different accelerators and how they can provide access to experts, community, and professional coaching for your startup journey.How transitioning from a specialized field like academia to a startup environment requires humility and a willingness to seek adviceThe importance of team culture for startup success, and how that differs from academia.What steps will you take today to cultivate your network and embrace new challenges?Thank you for listening! If you enjoyed this episode, take a screenshot of the episode to post in your stories and tag me!  And don't forget to follow, rate, and review the podcast and tell me your key takeaways!Learn more about How Women Inspire at https://www.howwomenlead.com/podcast CONNECT WITH GRACE WEI:LinkedInEncellinCONNECT WITH JULIE CASTRO ABRAMS:LinkedIn - JulieHow Women LeadHow Women InvestHow Women GiveInstagram - HWLLinkedIn - HWLFacebook - HWL

Winning the War on Cancer (Video)
Prostate Cancer Overview

Winning the War on Cancer (Video)

Play Episode Listen Later Jul 16, 2025 12:52


Prostate cancer remains the most commonly diagnosed cancer and second leading cause of cancer death among men in the U.S., with evolving screening and treatment practices reshaping care in 2025. UCSF's Dr. Matthew Cooperberg highlights a shift away from overdiagnosis and overtreatment of low-risk cancers, focusing instead on identifying aggressive disease through tools like MRI and advanced biomarker tests. A new “smarter screening” model now guides primary care, recommending long testing intervals for men with low PSA levels. While active surveillance has increased nationally, significant variation in care remains, and racial disparities—especially for Black men—persist. Patients are encouraged to take time in making treatment decisions, as prostate cancer often progresses slowly and allows for thoughtful, personalized care. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40796]

Health and Medicine (Video)
Prostate Cancer Overview

Health and Medicine (Video)

Play Episode Listen Later Jul 16, 2025 12:52


Prostate cancer remains the most commonly diagnosed cancer and second leading cause of cancer death among men in the U.S., with evolving screening and treatment practices reshaping care in 2025. UCSF's Dr. Matthew Cooperberg highlights a shift away from overdiagnosis and overtreatment of low-risk cancers, focusing instead on identifying aggressive disease through tools like MRI and advanced biomarker tests. A new “smarter screening” model now guides primary care, recommending long testing intervals for men with low PSA levels. While active surveillance has increased nationally, significant variation in care remains, and racial disparities—especially for Black men—persist. Patients are encouraged to take time in making treatment decisions, as prostate cancer often progresses slowly and allows for thoughtful, personalized care. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40796]

University of California Audio Podcasts (Audio)

Prostate cancer remains the most commonly diagnosed cancer and second leading cause of cancer death among men in the U.S., with evolving screening and treatment practices reshaping care in 2025. UCSF's Dr. Matthew Cooperberg highlights a shift away from overdiagnosis and overtreatment of low-risk cancers, focusing instead on identifying aggressive disease through tools like MRI and advanced biomarker tests. A new “smarter screening” model now guides primary care, recommending long testing intervals for men with low PSA levels. While active surveillance has increased nationally, significant variation in care remains, and racial disparities—especially for Black men—persist. Patients are encouraged to take time in making treatment decisions, as prostate cancer often progresses slowly and allows for thoughtful, personalized care. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40796]

Health and Medicine (Audio)
Prostate Cancer Overview

Health and Medicine (Audio)

Play Episode Listen Later Jul 16, 2025 12:52


Prostate cancer remains the most commonly diagnosed cancer and second leading cause of cancer death among men in the U.S., with evolving screening and treatment practices reshaping care in 2025. UCSF's Dr. Matthew Cooperberg highlights a shift away from overdiagnosis and overtreatment of low-risk cancers, focusing instead on identifying aggressive disease through tools like MRI and advanced biomarker tests. A new “smarter screening” model now guides primary care, recommending long testing intervals for men with low PSA levels. While active surveillance has increased nationally, significant variation in care remains, and racial disparities—especially for Black men—persist. Patients are encouraged to take time in making treatment decisions, as prostate cancer often progresses slowly and allows for thoughtful, personalized care. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40796]

Winning the War on Cancer (Audio)
Prostate Cancer Overview

Winning the War on Cancer (Audio)

Play Episode Listen Later Jul 16, 2025 12:52


Prostate cancer remains the most commonly diagnosed cancer and second leading cause of cancer death among men in the U.S., with evolving screening and treatment practices reshaping care in 2025. UCSF's Dr. Matthew Cooperberg highlights a shift away from overdiagnosis and overtreatment of low-risk cancers, focusing instead on identifying aggressive disease through tools like MRI and advanced biomarker tests. A new “smarter screening” model now guides primary care, recommending long testing intervals for men with low PSA levels. While active surveillance has increased nationally, significant variation in care remains, and racial disparities—especially for Black men—persist. Patients are encouraged to take time in making treatment decisions, as prostate cancer often progresses slowly and allows for thoughtful, personalized care. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40796]

Health and Medicine (Video)
Technology AI and People with Developmental Disabilities

Health and Medicine (Video)

Play Episode Listen Later Jul 14, 2025 35:29


As part of the 2025 Developmental Disabilities Conference, Yao Du from the Keck School of Medicine at USC, talk about the risks and benefits of technology and generative AI. Series: "Developmental Disabilities Update" [Health and Medicine] [Show ID: 40624]

University of California Audio Podcasts (Audio)
Technology AI and People with Developmental Disabilities

University of California Audio Podcasts (Audio)

Play Episode Listen Later Jul 14, 2025 35:29


As part of the 2025 Developmental Disabilities Conference, Yao Du from the Keck School of Medicine at USC, talk about the risks and benefits of technology and generative AI. Series: "Developmental Disabilities Update" [Health and Medicine] [Show ID: 40624]

Health and Medicine (Audio)
Technology AI and People with Developmental Disabilities

Health and Medicine (Audio)

Play Episode Listen Later Jul 14, 2025 35:29


As part of the 2025 Developmental Disabilities Conference, Yao Du from the Keck School of Medicine at USC, talk about the risks and benefits of technology and generative AI. Series: "Developmental Disabilities Update" [Health and Medicine] [Show ID: 40624]

Mind & Matter
Sleep Duration, Sleep Timing & Short-Sleepers | Ying-Hui Fu | 239

Mind & Matter

Play Episode Listen Later Jul 13, 2025 54:06


Send us a textThe genetics of sleep duration and sleep timing.Episode Summary: Dr. Ying-Hui Fu discusses her research on the genetics of sleep, focusing on natural short sleepers who thrive on 4-6 hours of sleep and the heritability of sleep traits like duration and timing. She explores how sleep efficiency, rather than just duration, may explain why some need less sleep without health deficits, and delves into the molecular and circadian mechanisms regulating sleep. About the guest: Ying-Hui Fu, PhD is a neuroscientist and professor at UCSF, where her lab studies the genetics of human sleep behaviors, particularly sleep duration and schedule.Discussion Points:Sleep Traits Are Genetic: Sleep duration (how long you sleep) and sleep schedule (when you sleep) are partially heritable, with most people needing 7-9 hours, while rare natural short sleepers thrive on 4-6 hours.Natural Short Sleepers: These individuals fall asleep quickly, have high sleep efficiency, and live healthy, active lives without deficits, possibly due to faster toxin clearance and repair during sleep.Sleep Efficiency Matters: Short sleepers may complete restorative sleep processes (e.g., clearing toxins, repairing damage) more efficiently, allowing them to need less sleep.Circadian & Entrainment Pathways: Sleep timing is regulated by a molecular clock and environmental cues like light, with mutations in entrainment pathways causing extreme schedules (e.g., early bedtime or night owl tendencies).Modern Lifestyle Harms Sleep: Stimuli like blue light and tense media disrupt sleep patterns, leading to widespread sleep deprivation and health risks.Shift Work Risks: Shift workers face higher risks of diseases like cancer and neurodegeneration due to disrupted sleep cycles, though genetic background influences susceptibility.Finding Your Sleep Rhythm: A two-week vacation without stimulants or artificial light can help determine your natural sleep schedule and duration.Sleep's Health Impact: Poor sleep is a major factor in aging and diseases like Alzheimer's, making it as critical as diet and exercise for health.Related episode:M&M 237: Circadian Biology: Genetics, Behavior, Metabolism, Light, OxygenSupport the showAll episodes, show notes, transcripts, and more at the M&M Substack Affiliates: KetoCitra—Ketone body BHB + potassium, calcium & magnesium, formulated with kidney health in mind. Use code MIND20 for 20% off any subscription (cancel anytime) Lumen device to optimize your metabolism for weight loss or athletic performance. Code MIND for 10% off Readwise: Organize and share what you read. 60 days FREE through link SiPhox Health—Affordable at-home blood testing. Key health markers, visualized & explained. Code TRIKOMES for a 20% discount. MASA Chips—delicious tortilla chips made from organic corn & grass-fed beef tallow. No seed oils or artificial ingredients. Code MIND for 20% off For all the ways you can support my efforts

AliveAndKickn's podcast
AliveAndKickn Podcast - Dr Aparajita Singh

AliveAndKickn's podcast

Play Episode Listen Later Jul 13, 2025 44:56


I sit down with Dr Aparajita Singh, Gastroenterologist and Director of the Lynch Syndrome Center at UCSF, where it truly is a team effort taking care of Lynch Syndrome patients.  Aside from me mispronouncing Lynch Syndrome, it was a wonderful engaging conversation.  UCSF Lynch Syndrome Center should have the links to everything discussed, which was a lot.  Check it out.        

Health and Medicine (Video)
College Bound For People with Autism

Health and Medicine (Video)

Play Episode Listen Later Jul 13, 2025 47:09


As part of the 2025 Developmental Disabilities Conference, Edlyn Peña, Professor of Educational Leadership Doctoral Program at California Lutheran University, Emma Cladis, a Vanguard University student, talk about college for people with autism. Series: "Developmental Disabilities Update" [Health and Medicine] [Show ID: 40612]

Ground Truths
Why Can't I Find and Get to the Right Doctor?

Ground Truths

Play Episode Listen Later Jul 13, 2025 32:27


Eric Topol (00:06):Hello, this is Eric Topol from Ground Truths, and I'm delighted to welcome Owen Tripp, who is a CEO of Included Health. And Owen, I'd like to start off if you would, with the story from 2016, because really what I'm interested in is patients and how to get the right doctor. So can you tell us about when you lost your hearing in your right ear back, what, nine years ago or so?Owen Tripp (00:38):Yeah, it's amazing to say nine years, Eric, but obviously as your listeners will soon understand a pretty vivid memory in my past. So I had been working as I do and noticed a loss of hearing in my right ear. I had never experienced any hearing loss before, and I went twice actually to a sort of national primary care chain that now owned by Amazon actually. And they described it as eustachian tube dysfunction, which is a pretty benign common thing that basically meant that my tubes were blocked and that I needed to have some drainage. They recommended Sudafed to no effect. And it was only a couple weeks later where I was walking some of the senior medical team at my company down to the San Francisco Giants game. And I was describing this experience of hearing loss and I said I was also losing a little bit of sensation in the right side of my face. And they said, that is not eustachian tube dysfunction. And well, I can let the story unfold from there. But basically my colleagues helped me quickly put together a plan to get this properly diagnosed and treated. The underlying condition is called vestibular schwannoma, even more commonly known as an acoustic neuroma. So a pretty rare benign brain tumor that exists on the vestibular nerve, and it would've cost my life had it not been treated.Eric Topol (02:28):So from what I gather, you saw an ENT physician, but that ENT physician was not really well versed in this condition, which is I guess a bit surprising. And then eventually you got to the right ENT physician in San Francisco. Is that right?Owen Tripp (02:49):Well, the first doctor was probably an internal medicine doctor, and I think it's fair to say that he had probably not seen many, if any cases. By the time I reached an ENT, they were interested in working me up for what's known as sudden sensorineural hearing loss (SSHL), which is basically a fancy term for you lose hearing for a variety of possible pathologies and reasons, but you go through a process of differential diagnosis to understand what's actually going on. By the time that I reached that ENT, the audio tests had showed that I had significant hearing loss in my right ear. And what an MRI would confirm was this mass that I just described to you, which was quite large. It was already about a centimeter large and growing into the inner ear canal.Eric Topol (03:49):Yeah, so I read that your Stanford brain scan suggested it was about size of a plum and that you then got the call that you had this mass in your brainstem tumor. So obviously that's a delicate operation to undergo. So the first thing was getting a diagnosis and then the next thing was getting the right surgeon to work on your brain to resect this. So how did you figure out who was the right person? Because there's only a few thousand of these operations done every year, as I understand.Owen Tripp (04:27):That's exactly right. Yeah, very few. And without putting your listeners to sleep too early in our discussion, what I'll say is that there are a lot of ways that you can actually do this. There are very few cases, any approach really requires either shrinking or removing that tumor entirely. My size of tumor meant it was really only going to be a surgical approach, and there I had to decide amongst multiple potential approaches. And this is what's interesting, Eric, you started saying you wanted to talk about the patient experience. You have to understand that I'm somebody, while not a doctor, I lead a very large healthcare company. We provide millions of visits and services per year on very complex medical diagnoses down to more standard day-to-day fare. And so, being in the world of medical complexity was not daunting on the basics, but then I'm the patient and now I have to make a surgical treatment decision amongst many possible choices, and I was able to get multiple opinions.Owen Tripp (05:42):I got an opinion from the House clinic, which is closer to you in LA. This is really the place where they invented the surgical approach to treating these things. I also got an approach shared with me from the Mayo Clinic and one from UCSF and one from Stanford, and ultimately, I picked the Stanford team. And these are fascinating and delicate structures as you know that you're dealing with in the brain, but the surgery is a long surgery performed by multiple surgeons. It's such an exhausting surgery that as you're sort of peeling away that tumor that you need relief. And so, after a 13 hour surgery, multiple nights in the hospital and some significant training to learn how to walk and move and not lose my balance, I am as you see me today, but it was possible under one of the surgical approaches that I would've lost the use of the right side of my face, which obviously was not an option given what I given what I do.Eric Topol (06:51):Yeah, well, I know there had to be a tough rehab and so glad that you recovered well, and I guess you still don't have hearing in that one ear, right?Owen Tripp:That's right.Eric Topol:But otherwise, you're walking well, and you've completely recovered from what could have been a very disastrous type of, not just the tumor itself, but also the way it would be operated on. 13 hours is a long time to be in the operating room as a patient.Owen Tripp (07:22):You've got a whole team in there. You've got people testing nerve function, you've got people obviously managing the anesthesiology, which is sufficiently complex given what's involved. You've got a specialized ENT called a neurotologist. You've got the neurosurgeon who creates access. So it's quite a team that does these things.Eric Topol (07:40):Yeah, wow. Now, the reason I wanted to delve into this from your past is because I get a call or email or whatever contact every week at least one, is can you help me find the right doctor for such and such? And this has been going on throughout my career. I mean, when I was back in 20 years ago at Cleveland Clinic, the people on the board, I said, well, I wrote about it in one of my books. Why did you become a trustee on the board? And he said, so I could get access to the right doctor. And so, this is amazing. We live in an information era supposedly where people can get information about this being the most precious part, which is they want to get the right diagnosis, they want to get the right treatment or prevention, whatever, and they can't get it. And I'm finding this just extraordinary given that we can do deep research through several different AI models and get reports generated on whatever you want, but you can't get the right doctor. So now let's go over to what you're working on. This company Included Health. When did you start that?Owen Tripp (08:59):Well, I started the company that was known as Grand Rounds in 2011. And Grand Rounds still to this day, we've rebranded as Included Health had a very simple but powerful idea, one you just obliquely referred to, which is if we get people to higher quality medicine by helping them find the right level and quality of care, that two good things would happen. One, the sort of obvious one, patients would get better, they'd move on with their lives, they'd return to health. But two and critically that we would actually help the system overall with the cost burden of unnecessary, inappropriate and low quality care because the coda to the example you gave of people calling you looking for a physician referral, and you and I both know this, my guess is you've probably had to clean plenty of it up in your career is if you go to the wrong doctor, you don't get out of the problem. The problem just persists. And that patient is likely to bounce around like a ping pong ball until they find what they actually need. And that costs the payers of healthcare in this country a lot of money. So I started the company in 2011 to try to solve that problem.Eric Topol (10:14):Yeah, one example, a patient of mine who I've looked after for some 35 years contacted me and said, a very close friend of mine lives in the Palm Springs region and he has this horrible skin condition and he's tortured and he's been to six centers, UCSF, Stanford, Oregon Health Science, Eisenhower, UCLA, and he had a full workup and he can't sleep because he's itching all the time. His whole skin is exfoliating and cellulitis and he had biopsies everywhere. He's put on all kinds of drugs, monoclonal antibodies. And I said to this patient of mine I said, I don't know, this is way out of my area. I checked at Scripps and turns out there was this kind of the Columbo of dermatology, he can solve any mystery. And the patient went to see him, and he was diagnosed within about a minute that he had scabies, and he was treated and completely recovered after having thousands and thousands of dollars of all these workups at these leading medical centers that you would expect could make a diagnosis of scabies.Owen Tripp (11:38):That's a pretty common diagnosis.Eric Topol (11:40):Yeah. I mean you might expect it more in somebody who was homeless perhaps, but that doesn't mean it can't happen in anyone. And within the first few minutes he did a scrape and showed the patient under the microscope and made a definitive diagnosis and the patient to this day is still trying to pay all his bills for all these biopsies and drugs and whatnot, and very upset that he went through all this for over a year and he thought he wanted to die, it was so bad. Now, I had never heard of Included Health and you have now links with a third of the Fortune 100 companies. So what do you do with these companies?Owen Tripp (12:22):Yeah, it's pretty cool. These companies, so very large organizations like Walmart and JPMorgan Chase and the rest of the big pioneers of American industry and business put us in as a benefit to help their employees have the same experience that I described to provide almost Eric Topol like guidance service to help people find access to high quality care, which might be referring them into the community or to an academic medical center, but often is also us providing care delivery ourselves through on-demand primary care, urgent care, behavioral health. And now just last year we introduced a couple of our first specialty lines. And the idea, Eric, is that these companies buy this because they know their employees will love it and they do. It is often one of, if not the most highly rated benefits available. But also because in getting their employees better care faster, the employees come back to work, they feel more connected to the company, they're able to do better and safer and higher quality work. And they get more mileage out of their health benefits. And you have to remember that the costs of health benefits in this country are inflating even in this time of hyperinflation. They're inflating faster than anything else, and this is one of most companies, number one pain points for how they are going to control their overall budget. So this is a solution that both give them visibility to controlling cost and can deliver them an excellent patient experience that is not an offer that they've been able to get from the traditional managed care operators.Eric Topol (14:11):So I guess there's a kind of multidimensional approach that you're describing. For one, you can help find a doctor that's the right doctor for the right patient. And you're also actually providing medical services too, right?Owen Tripp (14:27):That's right.Eric Topol (14:30):Are these physicians who are employed by Included Health?Owen Tripp (14:34):They are, and we feel very strongly about that. We think that in our model, we want to train people, hire people in a specific way, prepare them for the kind of work that we do. And there's a lot we could spend time talking about there, but one of the key features of that is teamwork. We want people to work in a collaborative model where they understand that while they may be expert in one specific thing that is connected to a service line, they're working in a much broader team in support of the member, in support of that patient. And we talk about the patients being very first here, and you and I had a laugh on this in the past, so many hospitals will say we're patient first. So many managed care companies will say they're patient first, but it is actually hard the way that the system is designed to truly be patient first. At Included Health, we measure whether patients will come back to us, whether they tell their friends about us, whether they have high quality member satisfaction and are they living more healthy days. So everybody gets surveyed for patient reported outcomes, which is highly unusual as you know, to have both the clinical outcomes and the patient reported outcomes as well.Eric Topol (15:41):Is that all through virtual visits or are there physical visits as well?Owen Tripp (15:47):Today that is all through virtual visits. So we provide 24/7/365 access to urgent care, primary care, behavioral health, the start of the specialty clinic, which we launched last year. And then we provide support for patients who have questions about how these things are going to be billed, what other benefits they have access to. And where appropriate, we send them out to care. So obviously we can't provide all the exams virtually. We can't provide everything that a comprehensive physical would today, but as you and I know that is also changing rapidly. And so, we can do things to put sensors and other observational devices in people's homes to collect that data positively.Eric Topol (16:32):Now, how is that different than Teladoc and all these other telehealth based companies? I mean because trying to understand on the one hand you have a service that you can provide that can be extremely helpful and seems to be relatively unique. Whereas the other seems to be shared with other companies that started in this telehealth space.Owen Tripp (16:57):I think the easiest way to think about the difference here is how a traditional telemedicine company is paid and how we're paid because I think it'll give you some clue as to why we've designed it the way we've designed it. So the traditional telehealth model is you put a quarter in the jukebox, you listen to a song when the song's over, you got to get out and move on with the rest of your life. And quite literally what I mean is that you're going to see one doctor, one time, you will never see that same doctor again. You are not going to have a connected experience across your visits. I mean, you might have an underlying chart, but there's not going to be a continuity of care and follow up there as you would in an integrated setting. Now by comparison, and that's all derived from the fact that those telehealth companies are paid by the drink, they're paid by the visit.Owen Tripp (17:49):In our model, we are committing to a set of experience goals and a set of outcomes to the companies that you refer to that pay our bill. And so, the visits that our members enjoy are all connected. So if you have a primary care visit, that is connected to your behavioral health visit, which is great and is as it should be. If you have a primary care appointment where you identify the need for follow-up cardiology for example. That patient can be followed through that cardiology visit that we circle back, that we make sure that the patient is educated, that he or she has all their questions answered. That's because we know that if the patient actually isn't confident in what they heard and they don't follow through on the plan, then it's all for naught. It's not going to work. And it's a simple sort of observation, but it's how we get paid and why we think it's a really important way to think about medicine.Eric Topol (18:44):So these companies, and they're pretty big companies like Google and AT&T and as you said, JPMorgan and the list goes on and on. Any one of the employees can get this. Is that how it works?Owen Tripp (18:56):That's right, that's right. And even better, most of what I've described to you today is at a low or zero cost to them. So this is a very affordable, easy way to access care. Thinking about one of our very large airline clients the other day, we're often dealing with their flight crews and ramp agents at very strange hours in very strange places away from home, so that they don't have to wait to get access to care. And you can understand that at a basic humanitarian level why that's great, but you can also understand it from a safety perspective that if there is something that is impeding that person's ability to be functioning at work, that becomes an issue for the corporation itself.Eric Topol (19:39):Yeah, so it's interesting you call it included because most of us in the country are excluded. That is, they don't have any way to turn through to get help for a really good referral. Everything's out of network if they are covered and they're not one of the fortunate to be in these companies that you're providing the service for. So do you have any peers or are there any others that are going to come into this space to help a lot of these people that are in a tough situation where they don't really have anyone to turn to?Owen Tripp (20:21):Well, I hope so. Because like you, I've dedicated my career to trying to use information and use science and use in my own right to bring along the model. At Included Health, we talk about raising the standard of care for everybody, and what we mean by that is, we actually hope that this becomes a model that others can follow. The same way the Cleveland Clinic did, the same way the Mayo Clinic did. They brought a model into the world that others soon try to replicate, and that was a good thing. So we'd like to see more attempt to do this. The reality is we have not seen that because unfortunately the old system has a lot of incentives in place to function exactly the way that it is designed. The health system is going to maximize the number of patients that correspond to the highest paying procedures and tests, et cetera. The managed care company is going to try to process the highest number of claims, work the most efficient utilization management and prior authorization, but left out in the middle of all of that is the patient. And so, we really wanted to build that model with the patient at the center, and when I started this company now over a decade ago, that was just a dream that we could do that. Now serving over 10 million members, this feels like it's possible and it feels like a model others could follow.Eric Topol (21:50):Yeah, well that was what struck me is here you're reaching 10 million people. I'd never heard of it. I was like, wow. I thought I try to keep up with things. But now the other thing I wanted to get into you with is AI. Obviously, that has a lot of promise in many different ways. As you know, there are some 12 million diagnostic serious errors a year in the US. I mean you were one, I've been part of them. Most people have been roughed up one way or another. Then there's 800,000 Americans who have disability or die from these errors a year, according to Johns Hopkins relatively recent study. So one of the ways that AI could help is accuracy. But of course, there's many other ways it can help make the lives of both patients helping to integrate their data and physicians to go through a patient's records and set points of their labs and all sorts of other things. Where do you see AI fitting into the model that you've built?Owen Tripp (22:58):Well, I'll give you two that I'm really excited about, that I don't think I hear other people talking about. And again, I'm going to start with that patient, with that member and what he or she wants and needs. One and Eric, bear with me, this is going to sound very banal, but one is just making sense of these very complicated plan documents and explanations of benefits. I'm aware of how well-trained you are and how much you've written. I believe you are the most published in your field. I believe that is a fact. And yet if I showed you a plan description document and an explanation of benefit and I asked you, Eric, could you tell me how much it's going to cost to have an MRI at this facility? I don't think you would've any way of figuring that out. And that is something that people confront every single day in this country. And a lot of people are not like you and me, in that we could probably tolerate a big cost range for that MRI. For some people that might actually be the difference between whether they eat or not, or get their kids prescription or not.Owen Tripp (24:05):And so, we want to make the questions about what your benefits cover and how you understand what's available to you in your plan. We want to make that really easy and we want to make it so that you don't have to have a PhD in insurance language to be able to ask the properly formatted question. As you know, the foundation models are terrific at that problem. So that's one.Eric Topol (24:27):And that's a good one, that's very practical and very much needed. Yeah.Owen Tripp (24:32):The second one I'm really excited about, and I think this will also be near and dear to your heart, is AI has this ability to be sort of nonjudgmental in the best possible way. And so, if we have a patient on a plan to manage hypertension or to manage weight or to manage other elements of a healthy lifestyle. And here we're not talking about deep science, we're just talking about what we've known to work for a long period of time. AI as a coach to help follow through on those goals and passively take data on how you're progressing, but have behind it the world's greatest medical team to be able to jump in when things become more acute or more complex. That's an awesome tool that I think every person needs to be carrying around, so that if my care plan or if my goal is about sleeping better, if my goal is about getting pregnant, if my goal is about reducing my blood pressure, that I can do that in a way that I can have a conversation where I don't feel as a patient that I'm screwing up or letting somebody down, and I can be honest with that AI.Owen Tripp (25:39):So I'm really excited about the potential for the AI as an adjunct coach and care team manager to continue to proceed along with that member with medical support behind that when necessary.Eric Topol (25:55):Yeah, I mean there's a couple of things I'd say about that. Firstly, the fact that you're thinking it from the patient perspective where most working in AI is thinking it from the clinician perspective, so that's really important. The next is that we get notifications, and you need to not sit every hour or something like that from a ring or from a smartwatch or whatever. That isn't particularly intelligent, although it may be needed. The point is we don't get notifications like, what was your blood pressure? Or can you send a PDF of your heart rhythm or this sort of thing. Now the problem too is that people are generating lots of data just by wearing a smartwatch or a fitness band. You've got your activity, your sleep, your heart rate, and all sorts of things that are derivatives of that. No less, you could have other sensors like a glucose monitoring and on and on. No less your electronic health record, and there's no integration of any of this.Eric Topol (27:00):So this idea that we could have a really intelligent AI virtual coach for the patient, which as you said could have connects with a physician as needed, bringing in the data or bringing in some type of issue that the doctor needs to attend to, but it doesn't seem like anything is getting done. We have the AI capabilities, but nothing's getting done. It's frustrating because I wrote about this in 2019 in the Deep Medicine book, and it's just like some of the most sophisticated companies you would think Apple, for the ring Oura and so many others. They have the data, but they don't integrate anything, and they don't really set up notifications for patients. How are we going to get out of this rut?Owen Tripp (27:51):We are producing oil tankers of data around personal experience and not actually turning that into positive energy for what patients can do. But I do want to be optimistic on this point because I actually think, and I shared this with you when we last saw each other. Your thinking was ahead of the time, but foundational for people like me to say, we need to go actually make that real. And let me explain to you what I mean by making it real. We need to bring together the insight that you have an elevated heart rate or that your step count is down, or that your sleep schedule is off. We need to bring that together with the possibility of connecting with a medical professional, which these devices do not have the ability to do that today, and nor do those companies really want to get in that business. And also make that context of what you can afford as a patient.Owen Tripp (28:51):So we have data that's suggestive of an underlying issue. We have a medical team that's prepared to actually help you on that issue. And then we have financial security to know that whatever is identified actually will be paid for. Now, that's not a hard triangle conceptually, but no one of those companies is actually interested in all the points of the triangle, and you have to be because otherwise it's not going to work for the patient. If your business is in selling devices. Really all I'm thinking about is how do I sell devices and subscriptions. If my business is exclusively in providing care, that's really all I'm thinking about. If my business is in managing risk and writing insurance policies, that's really all I'm thinking about. You have to do all those three things in concert.Eric Topol (29:34):Yeah, I mean in many ways it goes back to what we were talking about earlier, which is we're in this phenomenal era of information to the fifth power. But here we are, we have a lot of data from multiple sources, and it doesn't get integrated. So for example, a person has a problem and they don't know what is the root cause of it. Let's say it's poor sleep, or it could be that they're having stress, which would be manifest through their heart rate or heart rate variability or all sorts of other metrics. And there's no intelligence provided for them to interpret their data because it's all siloed and we're just not really doing that for patients. I hope that'll happen. Hopefully, Included Health could be a lead in that. Maybe you can show the way. Anyway, this has been a fun conversation, Owen. It's rare that I've talked in Ground Truths with any person running a company, but I thought yours.Eric Topol (30:36):Firstly, I didn't know anything about it and it's big. And secondly, that it's a kind of a unique model that really I'm hoping that others will get involved in and that someday we'll all be included. Maybe not with Included Health, but with better healthcare in this country, which is certainly not the norm, not the routine. And also, as you aptly pointed out at terrible costs with all sorts of waste, unnecessary tests and that sort of thing. So thanks for what you're doing and I'll be following your future efforts and hopefully we can keep making some strides.Owen Tripp (31:15):We will. And I wanted to say thanks for the conversation too and for your thinking on these topics. And look, I want to leave you just with a quick dose of optimism, and you and I both know this. The American system at its best is an extraordinary system, unrivaled in the world, in my opinion. But we do have to have more people included. All the services need to be included in one place. When we get there, we're going to really see what's possible here.Eric Topol (31:40):I do want to agree with you that if you can get to the right doctor and if you can afford it, that is ideally covered by your insurance. It is a phenomenal system, but getting there, that's the hard part. And every day people are confronted. I'm sure, thousands and thousands with serious condition either to get the diagnosis or the treatment, and they have a really rough time. So anyway, so thank you and I really appreciate your taking the time to meet with me today.****************************************************************Thanks for listening, watching, reading and subscribing to Ground Truths.An update on Super Agers:It is ranked #5 on the New York Times bestseller list (on the list for 4th time)https://www.nytimes.com/books/best-sellers/advice-how-to-and-miscellaneous/New podcastsPBS Walter Isaacson, Amanpour&Co Factually, With Adam ConoverPeter Lee, Microsoft Researchhttps://x.com/MSFTResearch/status/1943460270824714414If you found this interesting PLEASE share it!That makes the work involved in putting these together especially worthwhile.Thanks to Scripps Research, and my producer, Jessica Nguyen, and Sinjun Balabanoff for video/audio support.All content on Ground Truths—its newsletters, analyses, and podcasts, are free, open-access.Paid subscriptions are voluntary and all proceeds from them go to support Scripps Research. They do allow for posting comments and questions, which I do my best to respond to. Please don't hesitate to post comments and give me feedback. Let me know topics that you would like to see covered.Many thanks to those who have contributed—they have greatly helped fund our summer internship programs for the past two years. Get full access to Ground Truths at erictopol.substack.com/subscribe

University of California Audio Podcasts (Audio)
College Bound For People with Autism

University of California Audio Podcasts (Audio)

Play Episode Listen Later Jul 13, 2025 47:09


As part of the 2025 Developmental Disabilities Conference, Edlyn Peña, Professor of Educational Leadership Doctoral Program at California Lutheran University, Emma Cladis, a Vanguard University student, talk about college for people with autism. Series: "Developmental Disabilities Update" [Health and Medicine] [Show ID: 40612]

Health and Medicine (Audio)
College Bound For People with Autism

Health and Medicine (Audio)

Play Episode Listen Later Jul 13, 2025 47:09


As part of the 2025 Developmental Disabilities Conference, Edlyn Peña, Professor of Educational Leadership Doctoral Program at California Lutheran University, Emma Cladis, a Vanguard University student, talk about college for people with autism. Series: "Developmental Disabilities Update" [Health and Medicine] [Show ID: 40612]

Finding You: An Evoke Therapy Podcast
Psychedellic Assisted Psychotherapy - an Interview with Alexa Altman, Ph.D. - Ep 677

Finding You: An Evoke Therapy Podcast

Play Episode Listen Later Jul 11, 2025 58:21


Dr. Reedy welcomes Dr. Alexa Altman where she discusses how psychedelics bring the unconscious material into consciousness. She talks about the importance of integration. Dr. Altman's Website: https://www.i-psychedelic.com 1. Single-dose psilocybin (25 mg) with psychological support for MDDJAMA – “Single-Dose Psilocybin Treatment for Major Depressive Disorder” psychiatryonline.org+15sunstonetherapies.com+15pmc.ncbi.nlm.nih.gov+15 Summary: Demonstrated strong antidepressant effects and good tolerability over follow-up. Email: info@hopkinspsychedelic.org 2. One-Year Follow-Up of Psilocybin for Depression Study: Long-term effects of psilocybin therapy for depression Johns Hopkins – “Psilocybin treatment for major depression effective for up to a year” Summary: 67% of participants remained in remission one year post-treatment. 3. MDMA-Assisted Therapy for Severe PTSD Randomized, placebo-controlled MDMA-assisted therapy Nature Medicine – “MDMA-assisted therapy for severe PTSD” Summary: Significant reduction in PTSD symptoms, well‑tolerated in a diverse cohort. Contact (MAPS / Lykos Therapeutics): Email: info@maps.org 4. Psilocybin for Cancer-Related Anxiety & Depression Psilocybin in patients with life-threatening cancer PMC – “High-dose psilocybin produced large decreases in depressed mood and anxiety…” Summary: 80% of participants maintained significant symptom relief at 6 months. Website: heffter.org (contact via site) en.wikipedia.org 1. Johns Hopkins University Center for Psychedelic and Consciousness Research Psilocybin for depression, anxiety, addiction, and end-of-life distress Why it's top-tier: The first major U.S. institution to receive regulatory approval for psychedelic research in modern times.

Health and Medicine (Video)
Understanding the Diagnostic Label Autism

Health and Medicine (Video)

Play Episode Listen Later Jul 11, 2025 41:01


As part of the 2025 Developmental Disabilities Conference, Dr. Eric London talks about understanding autism. Series: "Developmental Disabilities Update" [Health and Medicine] [Show ID: 40618]

University of California Audio Podcasts (Audio)
Understanding the Diagnostic Label Autism

University of California Audio Podcasts (Audio)

Play Episode Listen Later Jul 11, 2025 41:01


As part of the 2025 Developmental Disabilities Conference, Dr. Eric London talks about understanding autism. Series: "Developmental Disabilities Update" [Health and Medicine] [Show ID: 40618]

Health and Medicine (Audio)
Understanding the Diagnostic Label Autism

Health and Medicine (Audio)

Play Episode Listen Later Jul 11, 2025 41:01


As part of the 2025 Developmental Disabilities Conference, Dr. Eric London talks about understanding autism. Series: "Developmental Disabilities Update" [Health and Medicine] [Show ID: 40618]

Translating Aging
Molecules to medicine: The translational landscape of aging interventions (Panel discussion at BAAM 2025)

Translating Aging

Play Episode Listen Later Jul 9, 2025 47:59


In this special episode, host Chris Patil (VP-Media, BioAge) moderates a live panel discussion at the 25th Bay Area Aging Meeting at UCSF, bringing together six leading voices across the aging research ecosystem to tackle one of the field's most critical challenges: how to move promising discoveries from the laboratory to therapies that can benefit patients.The distinguished panel spans academia, industry, and scientific publishing, featuring Janine Sengstack (CEO, Junevity), Saul Villeda (Professor, UCSF), Jodi Nunnari (Director, Bay Area Institute of Science, Altos Labs), Sebastien Thuault (Chief Editor, Nature Aging), Anne Brunet (Professor, Stanford), and Nir Barzilai (Professor, Albert Einstein College of Medicine). Together, they explore the most promising research directions for clinical impact, the revolutionary tools enabling modern aging research, and the structural challenges that must be overcome to bring longevity therapies to market.Listeners will gain insights into the emerging science of cellular rejuvenation, the importance of systemic factors in aging, how to balance high-risk discovery with practical drug development, and the cultural shifts needed to better prepare the next generation of scientists for translational work. The panel also addresses the regulatory challenges of targeting aging itself as an indication and offers candid advice for young researchers navigating this rapidly evolving field.The Finer Details:Emerging research directions with the greatest clinical potential: cellular senescence, rejuvenation and repair, DNA methylation clocks, and understanding what makes aging biomarkers tickThe revolution in cellular and spatial resolution tools and how single-cell technologies are revealing cell-type-specific aging responsesSystemic factors and the remarkable plasticity remaining in aging organisms that can be unlocked through interventionsThe critical importance of starting with human data and working backward to validate targets and approachesChallenges unique to aging biotech: the need for aging-specific cellular assays, testing in older animal models, and genetic validationCultural and structural barriers between academia and industry, including the shift from mechanism-focused to mission-driven researchBalancing high-risk fundamental discovery with the practical needs of drug development and clinical translationThe regulatory landscape for aging interventions and potential pathways to FDA approval beyond traditional disease indicationsAdvice for young scientists: embracing rejection as part of the process, finding passion, working as teams, and considering diverse career paths in the growing longevity ecosystemQuotes:"Our goal as a company is to increase human health span, and the way I like to frame that more colloquially is we want to increase the number of happy, healthy years each person gets to spend on Earth." - Janine Sengstack"There is an exquisite amount of plasticity left in an aging organism, both within the tissues, within the cells. There is plasticity that we can actually tap into." - Saul Villeda"Burn bright, but don't burn out." - Jodi Nunnari"The challenge that we run into is that there are so many combinations that very quickly it would become intractable to line up enough test tubes to test them all." - Sebastien Thuault, on the complexity of aging interventions"We love our job. If not, we would not be doing it. I would do it again in a heartbeat... you get paid to play, to ask the questions that interest you, the approaches that interest you to play with who you want to—it is a fantastic job." - Saul Villeda"Our life is a life of rejection...and still, we're having fun and making an advance. So don't give up." - Nir Barzilai

Ground Truths
New Center for Pediatric CRISPR Cures

Ground Truths

Play Episode Listen Later Jul 8, 2025 23:08


Eric Topol (00:05):Hello, it's Eric Topol from Ground Truths, and I've got some really exciting stuff to talk to you about today. And it's about the announcement for a new Center for pediatric CRISPR Cures. And I'm delight to introduce doctors Jennifer Doudna and Priscilla Chan. And so, first let me say this is amazing to see this thing going forward. It's an outgrowth of a New England Journal paper and monumental report on CRISPR in May. [See the below post for more context]Let me introduce first, Dr. Doudna. Jennifer is the Li Ka Shing Chancellor's Chair and a Professor in the departments of chemistry and of molecular and cell biology at the University of California Berkeley. She's also the subject of this book, one of my favorite books of all time, the Code Breaker. And as you know, the 2020 Nobel Prize laureate for her work in CRISPR-Cas9 genome editing, and she founded the Innovative Genomics Institute (IGI) back 10 years ago. So Jennifer, welcome.Jennifer Doudna (01:08):Thank you, Eric. Great to be here.Eric Topol (01:10):And now Dr. Priscilla Chan, who is the co-founder of the Chan Zuckerberg Initiative (CZI) that also was started back in 2015. So here we are, a decade later, these two leaders. She is a pediatrician having trained at UCSF and is committed to the initiative which has as its mission statement, “to make it possible to cure, prevent, and manage all diseases in this century.” So today we're going to talk about a step closer to that. Welcome, Priscilla.Priscilla Chan (01:44):Thank you. Thanks for having me.Eric Topol (01:46):Alright, so I thought we'd start off by, how did you two get together? Have you known each other for over this past decade since you both got all your things going?Jennifer Doudna (01:56):Yes, we have. We've known each other for a while. And of course, I've admired the progress at the CZI on fundamental science. I was an advisor very early on and I think actually that's how we got to know each other. Right, Priscilla?Priscilla Chan (02:11):Yeah, that's right. We got to know each other then. And we've been crisscrossing paths. And I personally remember the day you won the Nobel Prize. It was in the heart of the pandemic and a lot of celebrations were happening over Zoom. And I grabbed my then 5-year-old and got onto the UCSF celebration and I was like, look, this is happening. And it was really cool for me and for my daughter.Eric Topol (02:46):Well, it's pretty remarkable convergence leading up to today's announcement, but I know Priscilla, that you've been active in this rare disease space, you've had at CZI a Rare As One Project. Maybe you could tell us a bit about that.Priscilla Chan (03:01):Yeah, so at CZI, we work on basic science research, and I think that often surprises people because they know that I'm a pediatrician. And so, they often think, oh, you must work in healthcare or healthcare delivery. And we've actually chosen very intentionally to work in basic science research. In part because my training as a pediatrician at UCSF. As you both know, UCSF is a tertiary coronary care center where we see very unusual and rare cases of pediatric presentations. And it was there where I learned how little we knew about rare diseases and diseases in general and how powerful patients were. And that research was the pipeline for hope and for new discoveries for these families that often otherwise don't have very much access to treatments or cures. They have a PDF that maybe describes what their child has. And so, I decided to invest in basic science through CZI, but always saw the power of bringing rare disease patient cohorts. One, because if you've ever met a parent of a child with rare disease, they are a force to be reckoned with. Two, they can make research so much better due to their insights as patients and patient advocates. And I think they close the distance between basic science and impact in patients. And so, we've been working on that since 2019 and has been a passion of ours.Eric Topol (04:40):Wow, that's great. Now Jennifer, this IGI that you founded a decade ago, it's doing all kinds of things that are even well beyond rare diseases. We recently spoke, I know on Ground Truths about things as diverse as editing the gut microbiome in asthma and potentially someday Alzheimer's. But here you were very much involved at IGI with the baby KJ Muldoon. Maybe you could take us through this because this is such an extraordinary advance in the whole CRISPR Cures story.Jennifer Doudna (05:18):Yes, Eric. It's a very exciting story and we're very, very proud of the teamwork that went into making it possible to cure baby KJ of his very rare disease. And in brief, the story began back in August of last year when he was born with a metabolic disorder that prevented him from digesting protein, it's called a urea cycle disorder and rare, but extremely severe. And to the point where he was in the ICU and facing a very, very difficult prognosis. And so, fortunately his clinical team at Children's Hospital of Philadelphia (CHOP) reached out to Fyodor Urnov, who is the Director of Translational Medicine at the IGI here in the Bay Area. They teamed up and realized that they could quickly diagnose that child because we had an IRB approved here at the IGI that allowed us to collect patient samples and do diagnosis. So that was done.Jennifer Doudna (06:26):We created an off-the-shelf CRISPR therapy that would be targeted to the exact mutation that caused that young boy's disease. And then we worked with the FDA in Washington to make sure that we could very safely proceed with testing of that therapy initially in the lab and then ultimately in two different animal models. And then we opened a clinical trial that allowed that boy to be enrolled with, of course his parents' approval and for him to be dosed and the result was spectacular. And in fact, he was released from the hospital recently as a happy, healthy child, gaining lots of weight and looking very chunky. So it's really exciting.Eric Topol (07:16):It's so amazing. I don't think people necessarily grasp this. This timeline [see above] that we'll post with this is just mind boggling how you could, as you said Jennifer, in about six months to go from the birth and sequencing through cell specific cultures with the genome mutations through multiple experimental models with non-human primates even, looking at off-target effects, through the multiple FDA reviews and then dosing, cumulatively three dosing to save this baby's life. It really just amazing. Now that is a template. And before we go to this new Center, I just wanted to also mention not just the timeline of compression, which is unimaginable and the partnership that you've had at IGI with I guess Danaher to help manufacture, which is just another part of the story. But also the fact that you're not just even with CRISPR 1.0 as being used in approvals previously for sickle cell and β-thalassemia, but now we're talking about base editing in vivo in the body using mRNA delivery. So maybe you could comment on that, Jennifer.Jennifer Doudna (08:38):Yeah, very good point. So yeah, we used a version of CRISPR that was created by David Liu at the Broad Institute and published and available. And so, it was possible to create that, again, targeted to the exact mutation that caused baby KJ's disease. And fortunately, there was also an off-the-shelf way to deliver it because we had access to lipid nanoparticles that were developed for other purposes including vaccinations. And the type of disease that KJ suffered from is one that is treatable by editing cells in the liver, which is where the lipid nanoparticle naturally goes. So there were definitely some serendipity here, but it was amazing how all of these pieces were available. We just had to pull them together to create this therapy.Eric Topol (09:30):Yeah, no, it is amazing. So that I think is a great substrate for starting a new Center. And so, maybe back to you Priscilla, as to what your vision was when working with Jennifer and IGI to go through with this.Priscilla Chan (09:45):I think the thing that's incredibly exciting, you mentioned that at CZI our mission is to cure, prevent, and manage all disease. And when we talked about this 10 years ago, it felt like this far off idea, but every day it seems closer and closer. And I think the part that's super exciting about this is the direct connection between the basic science that's happening in CRISPR and the molecular and down to the nucleotide understanding of these mutations and the ability to correct them. And I think many of us, our imaginations have included this possibility, but it's very exciting that it has happened with baby KJ and CHOP. And we need to be able to do the work to understand how we can treat more patients this way, how to understand the obstacles, unblock them, streamline the process, bring down the cost, so that we better understand this pathway for treatment, as well as to increasingly democratize access to this type of platform. And so, our hope is to be able to do that. Take the work and inspiration that IGI and the team at CHOP have done and continue to push forward and to look at more cases, look at more organ systems. We're going to be looking in addition to the liver, at the bone marrow and the immune system.Priscilla Chan (11:17):And to be able to really work through more of the steps so that we can bring this to more families and patients.Eric Topol (11:30):Yeah, well it's pretty remarkable because here you have incurable ultra-rare diseases. If you can help these babies, just think of what this could do in a much broader context. I mean there a lot of common diseases have their roots with some of these very rare ones. So how do you see going forward, Jennifer, as to where you UC Berkeley, Gladstone, UCSF. I'm envious of you all up there in Northern California I have to say, will pull this off. How will you get the first similar case to KJ Muldoon going forward?Jennifer Doudna (12:13):Right. Well, IGI is a joint institute, as you probably know, Eric. So we were founded 10 years ago as a joint institute between UC Berkeley and UCSF. And now we have a third campus partner, UC Davis and we have the Gladstone Institute. So we've got an extraordinary group of clinicians and researchers that are coming together for this project and the Center to make it a success. We are building a clinical team at UCSF. We have several extraordinary leaders including Jennifer Puck and Chris Dvorak, and they are both going to be involved in identifying patients that could be enrolled in this program based on their diagnosis. And we will have a clinical advisory group that will help with that as well. So we'll be vetting patients probably right after we announce this, we're going to be looking to start enrolling people who might need this type of help.Eric Topol (13:18):Do you think it's possible to go any faster right now than the six months that it took for KJ?Jennifer Doudna (13:26):I think it could be. And here's the reason. There's a very interesting possibility that because of the type of technology that we're talking about with CRISPR, which fundamentally, and you and I have talked about this previously on your other podcast. But we've talked about the fact that it's a programmable technology and that means that we can change one aspect of it, one piece of it, which is a piece of a molecule called RNA that's able to direct CRISPR to the right sequence where we want to do editing and not change anything else about it. The protein, the CRISPR protein stays the same, the delivery vehicle stays the same, everything else stays the same. And so, we're working right now with FDA to get a platform designation for CRISPR that might allow streamlining of the testing process in some cases. So it'll obviously come down to the details of the disease, but we're hopeful that in the end it will be possible. And Priscilla and I have talked about this too, that as AI continues to advance and we get more and more information about rare diseases, we'll be able to predict accurately the effects of editing. And so, in some cases in the future it may be possible to streamline the testing process even further safely.Eric Topol (14:51):And I also would note, as you both know, well this administration is really keen on genome editing and they've had a joint announcement regarding their support. And in my discussions with the FDA commissioner, this is something they are very excited about. So the timing of the new Center for pediatric CRISPR Cures is aligned with the current administration, which is good to see. It's not always the case. Now going back, Priscilla, to your point that not just for the liver because delivery has been an issue of course, and we're going to try to get after a lot of these really rare diseases, it's going to go beyond there. So this is also an exciting new dimension of the Center, as you said, to go after the bone marrow for hematopoietic cells, perhaps other organs as well.Priscilla Chan (15:42):I mean what the expertise and feasibility, the immune system is going to be the next target. Jennifer Puck has been a pioneer in this work. She's the one who designed the newborn screen that will be the tool that picks up these patients as they are born. And I think the thing that's tremendous is the immune system, first of all is active in many, many diseases, not just these cases of children born with partial or absence of immune systems. And the course right now that these babies are left with is complete isolation and then a very long and arduous course of a bone marrow transplant with high morbidity and mortality. And even if after the transplant you have complications like graft versus host and immunosuppression. And so, the idea of being able to very specifically and with less the conditioning and morbidity and mortality of the treatment, being able to address this is incredible. And the implications for other diseases like blood cancers or other hematopoietic diseases, that's incredible. And that actually has an incredibly broad base of patients that can benefit from the learnings from these babies with severe combined immunodeficiencies.Eric Topol (17:10):Yeah, I think that goes back to a point earlier maybe to amplify in that previous CRISPR generation, it required outside the body work and it was extremely laborious and time consuming and obviously added much more to the expense because of hospitalization time. This is different. This is basically doing this inside the affected patient's body. And that is one of the biggest reasons why this is a big step forward and why we're so fortunate that your Center is moving forward. Maybe before we wrap up, you might want to comment, Jennifer on how you were able to bring in to build this platform, the manufacturing arm of it, because that seems to be yet another dimension that's helpful.Jennifer Doudna (18:01):Indeed, yes. And we were again fortunate with timing because you mentioned briefly that the IGI had set up a program with the Danaher Corporation back in January of last year. We call it our Beacon project. And it's focused on rare disease. And it's a really interesting kind of a unique partnership because Danaher is a manufacturing conglomerate. So they have companies that make molecules, they make proteins, they make RNA molecules, they make delivery molecules. And so, they were excited to be involved with us because they want to be a provider of these types of therapies in the future. And they can see the future of CRISPR is very exciting. It's expanding, growing area. And so, that agreement was in place already when the baby KJ case came to our attention. And so, what we're hoping to do with Danaher is again, work with them and their scientists to continue to ask, how can we reduce the cost of these therapies by reducing the cost of the molecules that are necessary, how to make them efficiently. We already, it's very interesting, Fyodor Urnov has toured their plant in North Dakota recently, and he found in talking to their engineers, there are a number of things that we can already see will be possible to do that are going to make the process of manufacturing these molecules faster and cheaper by a lot.Eric Topol (19:28):Wow.Jennifer Doudna (19:28):So it's a win-win for everybody. And so, we're really excited to do that in the context of this new Center.Eric Topol (19:36):Oh, that's phenomenal because some of these disorders you don't have that much time to work with before they could be brain or organ or vital tissue damage. So that's great to hear that. What you built here is the significance of it can't be under emphasized, I'll say because we have this May report of baby KJ, which could have been a one-off and it could have been years before we saw another cure of an ultra-rare disorder. And what you're doing here is insurance against that. You're going to have many more cracks at this. And I think this is the excitement about having a new dedicated Center. So just in closing, maybe some remarks from you Priscilla.Priscilla Chan (20:24):I just want to emphasize one point that's really exciting as we talk about these ultra-rare cases that they're often like one in a million. All these learnings actually help maximize the impact of lots of research across the sector that impacts actually everyone's health. And so, our learnings here from these patients that have very significant presentations that really can stand to benefit from any treatment is hopefully paving the way for many, many more of us to be able to live healthier, higher quality lives through basic science.Eric Topol (21:13):And over to you, Jennifer.Jennifer Doudna (21:15):Couldn't agree more. It's a really interesting moment. I think what we hope we are, is we're at sort of an inflection point where, as I mentioned earlier, all the pieces are in place to do this kind of therapeutic and we just need a team that will focus on doing it and pulling it together. And also learning from that process so that as Priscilla just said, we are ultimately able to use the same strategy for other diseases and potentially for diseases that affect lots of people. So it's exciting.Eric Topol (21:46):For sure. Now, if I could just sum up, this is now a decade past the origination of your work of CRISPR and how already at the first decade culminated in sickle cell disease treatment and β-thalassemia. Now we're into the second decade of CRISPR. And look what we've seen, something that was unimaginable until it actually happened and was reported just a little over a month ago. Now going back to Priscilla's point, we're talking about thousands of different rare Mendelian genomic disorders, thousands of them. And if you add them all up of rare diseases, we're talking about hundreds of millions of people affected around the world. So this is a foray into something much bigger, no less the fact that some of these rare mutations are shared by common diseases and approaches. So this really big stuff, congratulations to both of you and your organizations, the Innovative Genomics Institute and the Chan Zuckerberg Initiative for taking this on. We'll be following it with very deep interest, thank you.****************************************************Thanks for listening, reading and subscribing to Ground Truths.If you found this interesting PLEASE share it!That makes the work involved in putting these together especially worthwhile.Thanks to Scripps Research, and my producer, Jessica Nguyen, and Sinjun Balabanoff for video/audio support.All content on Ground Truths—its newsletters, analyses, and podcasts, are free, open-access.Paid subscriptions are voluntary and all proceeds from them go to support Scripps Research. They do allow for posting comments and questions, which I do my best to respond to. Please don't hesitate to post comments and give me feedback. Let me know topics that you would like to see covered.Many thanks to those who have contributed—they have greatly helped fund our summer internship programs for the past two years. Get full access to Ground Truths at erictopol.substack.com/subscribe

The Matt Walker Podcast
#101 - The Sleep Prescription To Better Immunity with Dr. Aric Prather

The Matt Walker Podcast

Play Episode Listen Later Jul 7, 2025 54:49


Matt welcomes UCSF sleep expert Dr. Aric Prather to the podcast this week to discuss the science of psychoneuroimmunology: the link between our behavior and immune health. After a primer on the immune system's innate and adaptive arms, Dr. Prather details how insufficient sleep dramatically increases your risk of catching a cold, significantly blunts vaccine effectiveness by reducing antibody response, and promotes a state of chronic, low-grade inflammation - a known pathway to numerous age-related diseases.Ultimately, the conversation illuminates a profound and actionable truth: sleep is arguably our most powerful, yet tragically overlooked, weapon in the daily battle for immunological health.Please note that Matt is not a medical doctor, and none of the content in this podcast should be considered medical advice in any way, shape, or form, nor prescriptive in any way.One of our sponsors this week is the biochemical electrolyte drink company LMNT, and they are very kindly offering eight free sample packs when you purchase any one of their orders at drinklmnt.com/mattwalker. LMNT is an electrolyte sports drink that I can get behind - it's created from the basis of science, and it has no sugar, no coloring, and no artificial ingredients – all qualities that are so important to maintaining your blood biochemical balance. And now their new Lemonade Salt is squeezing onto the scene Tuesday, May 20th! This limited-time flavor is here to keep you at your best all summer long, and, just like summer, it's here for a good time, not a long time, so stock up while supplies last! If you want to give Lemonade Salt or any of the fantastic LMNT flavors a try, just head on over to drinklmnt.com/mattwalker and get your free Sample Pack with your first purchase.Matt will be the first to tell you that launching his sleep-related merchandise sales was incredibly smooth, thanks to our new sponsor Shopify and their integrated sales and inventory system. And now, just for you,  Shopify is generously offering an exclusive trial at shopify.com/mattwalker. Whether it's online or in-person sales, Shopify simplifies it all. So, be sure to stop in at shopify.com/mattwalker to start your exclusive journey now! Matt's good friend Dr. Peter Attia has helped develop David, a revolutionary new protein bar, and a sponsor of today's episode! 28g of protein, 0g sugar, only 150 calories – the best ratio EVER! Amazing taste, six flavors, incredibly satiating, and a great source of the protein that helps build muscle, manage metabolic health, and keep you full. Visit davidprotein.com/mattwalker now for an amazing deal: Buy 4 cartons, and get a 5th FREE! . Hurry! Your new favorite protein bar awaits!As always, if you have thoughts or feedback you'd like to share, please reach out:Matt: Instagram @drmattwalker, X @sleepdiplomat, YouTube https://www.youtube.com/@sleepdiplomatmattwalker9299Dr. Aric Prather: https://www.aricprather.com/

Health and Medicine (Video)
Medication Shortages for ADHD and Other Conditions

Health and Medicine (Video)

Play Episode Listen Later Jul 7, 2025 42:36


As part of the 2025 Developmental Disabilities Conference, Marta E. Wosińska from the Center on Health Policyat The Brookings Institution talks about medication shortages. Series: "Developmental Disabilities Update" [Health and Medicine] [Show ID: 40616]

University of California Audio Podcasts (Audio)
Medication Shortages for ADHD and Other Conditions

University of California Audio Podcasts (Audio)

Play Episode Listen Later Jul 7, 2025 42:36


As part of the 2025 Developmental Disabilities Conference, Marta E. Wosińska from the Center on Health Policyat The Brookings Institution talks about medication shortages. Series: "Developmental Disabilities Update" [Health and Medicine] [Show ID: 40616]

Health and Medicine (Audio)
Medication Shortages for ADHD and Other Conditions

Health and Medicine (Audio)

Play Episode Listen Later Jul 7, 2025 42:36


As part of the 2025 Developmental Disabilities Conference, Marta E. Wosińska from the Center on Health Policyat The Brookings Institution talks about medication shortages. Series: "Developmental Disabilities Update" [Health and Medicine] [Show ID: 40616]

The Pituitary World News Podcast
S11E5: When It Looks Like Cushing's But It Isn't

The Pituitary World News Podcast

Play Episode Listen Later Jul 2, 2025 29:26


We are delighted to welcome Dr. Leena Shahla to the Pituitary Podcast. She is the director of The Duke Pituitary Program. Today she joins PWN co-founder and medical director of the California Center for Pituitary Disorders at UCSF, Dr. Lewis Blevins, for an in-depth discussion about pseudo-Cushing's syndrome. In the Duke Health web portal, Dr. Shahla says endocrinology captured her heart because it combines medical science with unique challenges. "My passion for solving puzzles drives my deep interest in pituitary disease, the most complex area of endocrinology." You can read more about Dr. Shahla, her practice and background here. This is a fascinating discussion about a complex, often misunderstood condition by two of the leading experts in the field you won't want to miss it. Pseudo-Cushing's syndrome or non-neoplastic hypercortisolism is a medical condition in which people with this disorder display the signs, symptoms, and abnormal cortisol levels.  Common causes can include  pregnancy, alcohol use disorder, morbid obesity, polycystic ovarian syndrome, end-stage renal disease, severe major depressive disorder, and poorly controlled diabetes.

Health and Medicine (Video)
Autism Screams in the Emergency Department: De-Escalation of the Agitated Autistic Patient

Health and Medicine (Video)

Play Episode Listen Later Jul 2, 2025 49:25


As part of the 2025 Developmental Disabilities Conference, Dr. Whitney Deal, an emergency physician at MedStar Union Memorial Hospital, talks about using the least restrictive approach when dealing with an agitated autistic patient. Series: "Developmental Disabilities Update" [Health and Medicine] [Show ID: 40614]

University of California Audio Podcasts (Audio)
Autism Screams in the Emergency Department: De-Escalation of the Agitated Autistic Patient

University of California Audio Podcasts (Audio)

Play Episode Listen Later Jul 2, 2025 49:25


As part of the 2025 Developmental Disabilities Conference, Dr. Whitney Deal, an emergency physician at MedStar Union Memorial Hospital, talks about using the least restrictive approach when dealing with an agitated autistic patient. Series: "Developmental Disabilities Update" [Health and Medicine] [Show ID: 40614]

Health and Medicine (Audio)
Autism Screams in the Emergency Department: De-Escalation of the Agitated Autistic Patient

Health and Medicine (Audio)

Play Episode Listen Later Jul 2, 2025 49:25


As part of the 2025 Developmental Disabilities Conference, Dr. Whitney Deal, an emergency physician at MedStar Union Memorial Hospital, talks about using the least restrictive approach when dealing with an agitated autistic patient. Series: "Developmental Disabilities Update" [Health and Medicine] [Show ID: 40614]

The BMJ Podcast
Time to rethink GP's advice on weightloss, and ticagrelor data doubts

The BMJ Podcast

Play Episode Listen Later Jul 1, 2025 33:38


Last December, The BMJ published an investigation into the 2009 PLATO trial - exposing serious problems with that study's data analysis and reporting.  Our follow up investigation has shown that those data problems extend to other key supporting evidence in AstraZeneca's initial application to regulators. Peter Doshi, senior editor in the BMJ's Investigations unit, and Rita Redberg, cardiologist and Professor of Medicine at UCSF and former editor of JAMA Internal Medicine, join us to explain what this means for scientific integrity, and trust in the FDA's approval processes.   Also in this episode. A group of international authors are arguing that weightloss advice given in primary care might actually be doing more harm than good - it's ineffective and potentially reinforces damaging stigma.  To explain why they came to that conclusion we're joined by Juan Franco editor in chief of BMJ EBM, and a practicing GP in Germany, and Emma Grundtvig Gram, from the Centre for General Practice at the University of Copenhagen Reading list Doubts over landmark heart drug trial: ticagrelor PLATO study Ticagrelor doubts: inaccuracies uncovered in key studies for AstraZeneca's billion dollar drug Beyond body mass index: rethinking doctors' advice for weight loss

6-8 Weeks: Perspectives on Sports Medicine
Break Down The Myths Behind Running

6-8 Weeks: Perspectives on Sports Medicine

Play Episode Listen Later Jun 30, 2025 19:06


Are you an experienced runner or simply starting out as a beginner? Listen to our latest podcast as we break down all aspects of running including injuries, arthritis risk, shoe wear, and the benefits of cross training.

KPFA - The Pacifica Evening News, Weekdays
SF Pride weekend kicks off with Trans March; Senate rejects War Powers Act limiting war without Congress approval – June 27, 2025

KPFA - The Pacifica Evening News, Weekdays

Play Episode Listen Later Jun 27, 2025 59:58


Comprehensive coverage of the day's news with a focus on war and peace; social, environmental and economic justice. SF Trans March SF Pride weekend kicks off with Trans March despite backlash from Trump administration, courts Newsom, Sen Padilla join activists warning “Big Beautiful Bill” could devastate CA healthcare Senate rejects War Powers Act requiring congress vote before going to war Israeli Haaretz news reports Israeli officers shoot food seekers as “crowd control” Housing activists introduce legislation against criminalization of homelessness Healthcare workers protest UCSF layoffs of 200 frontline workers, demand reinstatement The post SF Pride weekend kicks off with Trans March; Senate rejects War Powers Act limiting war without Congress approval – June 27, 2025 appeared first on KPFA.

NeurologyLive Mind Moments
144: Differentiating Dravet and Lennox-Gastaut: Diagnosis, Research, and What's Ahead

NeurologyLive Mind Moments

Play Episode Listen Later Jun 27, 2025 17:38


Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "Differentiating Dravet and Lennox-Gastaut: Diagnosis, Research, and What's Ahead," Joseph Sullivan, MD, director of the Pediatric Epilepsy Center at UCSF, joins Mind Moments to discuss the clinical distinctions between Dravet syndrome and Lennox-Gastaut syndrome (LGS). Sullivan outlines the unique diagnostic profiles, seizure presentations, and genetic underpinnings of each disorder, while also addressing how genetic testing has transformed the approach to Dravet syndrome in particular. He speaks on the future of targeted therapies, highlighting ongoing research in disease-modifying treatments and n-of-1 trials, especially for ultra-rare epilepsies. Additionally, Sullivan explores how the clinical trial landscape is evolving—emphasizing the need for biomarkers, innovative trial design, and better tools for seizure monitoring to improve outcomes in these complex pediatric epilepsies. Looking for more Epilepsy discussion? Check out the NeurologyLive® Epilepsy clinical focus page. Episode Breakdown: 1:00 – Key differences in phenotype and diagnosis between Dravet syndrome and LGS 3:00– The evolution of genetic testing and how it's improved Dravet diagnosis and outcomes 5:25 – Opportunities and limitations in scaling genetic testing more broadly 6:35 – Neurology News Minute 8:45 – Research pipelines: disease-modifying therapies, n-of-1 trials, and future directions 10:20 – Innovations in clinical trial design and the need for better seizure monitoring and biomarkers The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: European Commission Approves Efgartigimod Subcutaneous Injection for Forms of CIDP FDA Greenlights Expanded Indication for Vizamyl in Alzheimer Disease Diagnosis Grace Therapeutics Submits NDA for GTX-104 to Treat Aneurysmal Subarachnoid Hemorrhage Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Business Trip
The 4-Hour Sleepers Redefining Human Limits with Ying-Hui Fu of UCSF

Business Trip

Play Episode Listen Later Jun 26, 2025 33:11


Matias and Greg interview Ying-Hui Fu, PhD, is a Professor of Neurology at UCSF and a world leader in the genetics of sleep. Her lab has discovered the first-known genes behind “natural short sleepers”. Her work bridges human genetics and neuroscience to uncover how to modulate sleep for brain health, aging, and neurodegenerative diseases.In this episode, we discuss:How some people thrive on 4–6 hours of sleep with rare genetic mutationsWhy sleep efficiency is more important than total hours sleptWhat short sleeper genes reveal about preventing Alzheimer's and autismWhy current sleep research tools miss deeper brain activity patternsWhat's next in sleep science with potential therapiesCredits:Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Caitlin Ner & Nico V. Rey Find us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank

Winning the War on Cancer (Video)
Prostate Cancer: Demystifying Clinical Trials

Winning the War on Cancer (Video)

Play Episode Listen Later Jun 26, 2025 9:32


UCSF's Dr. Rahul Aggarwal explains the role of clinical trials in advancing prostate cancer treatment and how trial design is evolving to match today's more personalized approaches. He highlights how UCSF has contributed to major prostate cancer therapies and emphasizes the importance of genetic and genomic testing in identifying suitable trials for each patient. Dr. Aggarwal explains the different trial phases, clarifies common myths—such as concerns about placebos—and stresses that trials are considered at every stage of disease. He also discusses efforts to improve access, affordability, and diversity in trial participation, including regional partnerships and digital matching tools. The talk encourages patients to be informed and proactive when considering clinical trials as part of their treatment plan. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40800]

Health and Medicine (Video)
Prostate Cancer: Demystifying Clinical Trials

Health and Medicine (Video)

Play Episode Listen Later Jun 26, 2025 9:32


UCSF's Dr. Rahul Aggarwal explains the role of clinical trials in advancing prostate cancer treatment and how trial design is evolving to match today's more personalized approaches. He highlights how UCSF has contributed to major prostate cancer therapies and emphasizes the importance of genetic and genomic testing in identifying suitable trials for each patient. Dr. Aggarwal explains the different trial phases, clarifies common myths—such as concerns about placebos—and stresses that trials are considered at every stage of disease. He also discusses efforts to improve access, affordability, and diversity in trial participation, including regional partnerships and digital matching tools. The talk encourages patients to be informed and proactive when considering clinical trials as part of their treatment plan. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40800]

Health and Medicine (Video)
Autism Community Intervention for Suicide Prevention

Health and Medicine (Video)

Play Episode Listen Later Jun 25, 2025 43:48


As part of the 2025 Developmental Disabilities Conference, Anne V. Kirby, Associate Professor, University of Utah, talks about suicide prevention in the autism community. Series: "Developmental Disabilities Update" [Health and Medicine] [Show ID: 40610]

Mental Health and Psychiatry (Audio)
Autism Community Intervention for Suicide Prevention

Mental Health and Psychiatry (Audio)

Play Episode Listen Later Jun 25, 2025 43:48


As part of the 2025 Developmental Disabilities Conference, Anne V. Kirby, Associate Professor, University of Utah, talks about suicide prevention in the autism community. Series: "Developmental Disabilities Update" [Health and Medicine] [Show ID: 40610]

The Doctor's Farmacy with Mark Hyman, M.D.
Anxiety, Autism, Allergies: The Hidden Triggers in Children No One Talks About

The Doctor's Farmacy with Mark Hyman, M.D.

Play Episode Listen Later Jun 23, 2025 71:10


Rates of chronic illness, behavioral disorders, and neurodevelopmental challenges are rising rapidly among children, often tied to underlying gut dysfunction, nutrient deficiencies, and environmental triggers such as toxins and ultra-processed foods. Conventional treatments frequently overlook these root causes, relying instead on symptom management or medication. Functional approaches emphasize foundational lifestyle changes—clean nutrition, microbiome support, movement, sleep, and stress reduction—as powerful tools to restore health. Children are especially responsive to these changes, often experiencing rapid and dramatic improvements in behavior, mood, and physical symptoms. With education, testing, and family-centered strategies, parents can take simple, effective steps to help their children thrive. In this episode, I discuss, along with Dr. Elisa Song, Dr. Suzanne Goh, and Dr. Elizabeth Boham why a root-cause approach is just as important for children, as it is for adults. Dr. Elisa Song, MD is a Stanford-, NYU-, UCSF-trained integrative pediatrician, pediatric functional medicine expert, and mom to 2 thriving children - and she is on a mission to revolutionize the future of children's health. Dr. Song is the bestselling author of the Healthy Kids Happy Kids: An Integrative Pediatrician's Guide to Whole Child Resilience. Dr. Song created Healthy Kids Happy Kids as an online holistic pediatric resource to help practitioners and parents bridge the gap between conventional and integrative pediatrics with an evidence-based, pediatrician-backed, mom-approved approach. In her integrative pediatric practice, she's helped 1000s of kids get to the root causes of their health concerns and empowered parents to help their children thrive by integrating conventional pediatrics with functional medicine, homeopathy, acupuncture, herbal medicine, and essential oils. Dr. Song is chair of A4M's pediatric education and has lectured around the world at leading integrative and functional medicine conferences and premier parenting events. She has also been featured in hundreds of top podcasts, print and online media outlets, including the Wellness Mama podcast, BloomTV, Forbes, Healthline, MindBodyGreen, National Geographic, PopSugar, Parents, Motherly, Parade, Verywell Health, and New York Post. Dr. Suzanne Goh, co-founder and chief medical officer at Cortica, is a Rhodes Scholar and graduate of Harvard University, University of Oxford, and Harvard Medical School who has spent decades working with autistic children. Her work as a board-certified pediatric behavioral neurologist, behavioral analyst, neuroscience researcher, and author led her to create the Cortica Care Model, an innovative, whole-child approach that combines optimal medical treatment with the most effective strategies for advancing cognition, communication, and behavior. Dr. Elizabeth Boham is Board Certified in Family Medicine from Albany Medical School, and she is an Institute for Functional Medicine Certified Practitioner and the Medical Director of The UltraWellness Center. Dr. Boham lectures on a variety of topics, including Women's Health and Breast Cancer Prevention, insulin resistance, heart health, weight control and allergies. She is on the faculty for the Institute for Functional Medicine. This episode is brought to you by BIOptimizers. Head to bioptimizers.com/hyman and use code HYMAN10 to save 10%. Full-length episodes can be found here: How to Raise Healthy Kids: A Functional Medicine Approach The Surprising Causes of Autism & Why It's On The Rise Addressing The Root Causes Of Childhood Obesity

Everyday Wellness
BONUS: A Unique Perspective on Perimenopause and Menopause with Dr. Louann Brizendine

Everyday Wellness

Play Episode Listen Later Jun 23, 2025 63:28


I was happy to connect with Dr. Louann Brizendine today! She is the founder of the Women's Mood and Hormone Clinic at UCSF. She completed her degree in Neurobiology at the University of California, Berkeley, graduated from Yale School of Medicine, and completed her internship and residency at Harvard Medical School. She also served on the faculty of Harvard University and the University of California, San Francisco. Dr. Brizendine founded the Women's Mood and Hormone Clinic at UCSF. Her New York Times bestseller, The Female Brain, and its follow-up, The Male Brain, continue to be read worldwide.  Today, we dive deeply into her new book, The Upgrade: How the Female Brain Gets Stronger and Better in Midlife and Beyond, which was released in April 2022. IN THIS EPISODE YOU WILL LEARN: The transition and the upgrade stage of life explained Celebrating the transitional time of life and not fearing it How hormones help guide behavior Transition Stages 1,2,3 and what they mean Then onward to the 3 stages of "The Upgrade" Estrogen fluctuations that affect sleep Be aware of caffeine in your food and drinks and how it may affect your sleep. If you are having a problem staying asleep, you may want to cut back on alcohol or drink it earlier in the day. The Women's Health Initiative - (almost 20 years ago) disastrous misinterpretations and negative implications it caused by instilling fear in women to not use Estrogen - including osteoporosis, brain fog, anxiety, and sleep disruptions Hormone Replacement Therapy - now viewed as a positive and much-needed step in women's health Women between the ages of 40-50 should get a bone density scan as one of the determining factors of whether or not to begin hormone replacement therapy. Dr. Brizendine suggests that women should not be fearful of using therapies today to help balance hormones. Cynthia discusses the loss of cognition later in life as another correlative symptom of not receiving needed hormones. Dr. Brizendine advocates doing your own research regarding HRT and not depending only on information from major pharmaceutical companies. Cynthia and Dr. Brizendine discuss the importance of keeping an open mind when it comes to synthetic hormones because of the good they can do. If you are not well and do not feel like you can go on, please, immediately, seek out a doctor who can prescribe medications or hormones to help your particular and unique situation. Be your best and do not suffer in silence any longer. Cynthia says the transitional time of life should and can be a very good time in your life. Consider reading Dr. Brizendine's book(s) to learn more and to keep it as a valuable resource.  Connect with Cynthia Thurlow Follow on X, ⁠Instagram⁠ & ⁠LinkedIn⁠ Check out Cynthia's ⁠website⁠  Connect with Dr. Brizendine ⁠Website⁠ ⁠Facebook⁠ ⁠Instagram⁠ ⁠LinkedIn⁠ ⁠TikTok⁠ Dr. Louann Brizendine's Books ⁠The Upgrade⁠ (newest book) ⁠The Female Brain⁠ ⁠The Male Brain⁠ Resource Mentioned ⁠NAMS - North American Menopause Website

GeriPal - A Geriatrics and Palliative Care Podcast
Transgender Health, Aging, and Advocacy: A Podcast with Noelle Marie Javier and Jace Flatt

GeriPal - A Geriatrics and Palliative Care Podcast

Play Episode Listen Later Jun 19, 2025 48:24


Happy Pride Month GeriPal listeners! Transgender issues are in the news. Just today (June 17th) as we record this podcast: Ezra Klein released a wonderful interview with Sarah McBride, the first openly transgender member of congress A judge ruled that cuts to NIH grants focused on minority groups, including transgender people, were illegal and ordered the government to restore funding.  It's Pride month, and our guests remind us of the leadership of two trans women in the Stonewall riots, which started the modern fight for LGBTQI+ rights and liberation. Today's guests are Noelle Marie Javier, a geriatrician and palliative care doc who tells her story of transitioning as a faculty member at Mt. Sinai in New York, and Jace Flatt, who started their journey as a gerontology researcher at UCSF and is now faculty at UNLV. Jace was in the news recently for having multiple federal grants cancelled because they included transgender participants. We cover many topics, including: Terminology: gender identity, sexual orientation, gender expression, transgender, nonbinary, intersex, what's in LGBTQI+ Gender affirming care Major health and medical issues associated with aging as a transgender person Allostatic load Accelerated aging What can clinicians do - pointers, pearls, and attitudes Dementia risk  Caregiver issues Hormone replacement therapy at the end of life Sexual orientation and gender identity (SOGI) data, what is it, how to collect it respectfully and safely Mentioned: Harvey Chochinov's Dignity Therapy question, and our prior podcast on LGBT Care for older adults and serious illness with Carey Candrian and Angela Primbas So pleased to sing True Colors by Cyndi Lauper, with Kai on guitar for those of you listening to the podcast. -Alex Smith Many links! -Rainbows of Aging: Jace Flatt's research site. -LGBTQcaregivers -Callen-Lorde gender affirming trans health services -GLMA: organization for health professional advancing LGBTQ+ equality -Center of Excellence for Transgender Health at UCSF -World Professional Association for Transgender Health -Sage advocacy services for LGBTQ+ Elders: focus on impact of Medicaid cuts -Trans bodies, Trans selves: resource guide 

Democracy Now! Audio
Democracy Now! 2025-06-06 Friday

Democracy Now! Audio

Play Episode Listen Later Jun 6, 2025 59:00


Headlines for June 06, 2025; Musk vs. Trump? Quinn Slobodian on the Risks of Billionaire Rule; Trump Budget Bill Would Lead to 51,000 More Deaths Each Year, as Health Experts Urge Medicare for All; “Completely Unwarranted”: Newark Mayor Ras Baraka Sues Trump Officials over His Arrest at ICE Jail; High Seas Update from Aid Ship Sailing to Gaza: Activists Vow to “Win Through Solidarity”; Fired over Gaza? Dr. Rupa Marya Sues UCSF, Says She Was Targeted for Speaking Up for Palestine

Raising Good Humans
Understanding Orchids and Dandelions: A Deeper Dive into Human Temperament with Dr. Thomas Boyce

Raising Good Humans

Play Episode Listen Later Jun 6, 2025 66:12


In today's episode I sit down with Dr. Thomas Boyce, professor of pediatrics and psychiatry at UCSF, about his 40 years of research on temperamental differences in children, specifically focusing on his concept of 'orchid' and 'dandelion' children. Dr. Boyce explains how while most children are resilient like dandelions, a significant minority are sensitive 'orchids' who react more strongly to their environments. We discuss Boyce's research, the biological underpinnings of these temperamental differences, and how different environments impact these children.I WROTE MY FIRST BOOK! Order your copy of The Five Principles of Parenting: Your Essential Guide to Raising Good Humans Here: https://bit.ly/3rMLMsLSubscribe to my free newsletter for parenting tips delivered straight to your inbox: draliza.substack.com Follow me on Instagram for more:@raisinggoodhumanspodcast Sponsors:Ground News: Go to https://groundnews.com/HUMANS to get 40% off the unlimited access Vantage plan–the same plan that I use to stay informedIris & Romeo: Visit IrisandRomeo.com and use code HUMANS at checkout for 20% off your first purchaseActive Skin Repair: Visit https://www.ActiveSkinRepair.com to learn more about Active Skin Repair and to get 20% off your order, use code:HUMANSWater Wipes: Visit WaterWipes.com to learn more about how Water Wipes effectively cleans with minimal ingredients that leave nothing behindKiwico: Get $15 off on your Summer Adventure Series at kiwico.com/RGHQuince: Go to Quince.com/humans for free shipping on your order and three hundred and sixty-five-day returnsPlease note that this episode may contain paid endorsements and advertisements for products and services. Individuals on the show may have a direct or indirect financial interest in products or services referred to in this episode.Produced by Dear Media.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.